Insider Selling: Fractyl Health, Inc. (NASDAQ:GUTS) CEO Sells 90,972 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) CEO Harith Rajagopalan sold 90,972 shares of the business's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $1.82, for a total value of $165,569.04. Following the transaction, the chief executive officer now directly owns 491,329 shares in the company, valued at $894,218.78. This trade represents a 15.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Harith Rajagopalan also recently made the following trade(s):

• On Monday, November 11th, Harith Rajagopalan sold 96,517 shares of Fractyl Health stock. The shares were sold at an average price of $2.47, for a total transaction of $238,396.99.

Fractyl Health Stock Down 6.2 %

Shares of NASDAQ:GUTS traded down $0.10 during trading on Friday, hitting $1.51. The company's stock had a trading volume of 282,585 shares, compared to its average volume of 407,031. The company has a market capitalization of $72.63 million and a PE ratio of -0.12. Fractyl Health, Inc. has a fifty-two week low of $1.51 and a fifty-two week high of $10.69. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58. The stock's 50-day moving average price is $2.01 and its two-hundred day moving average price is $2.46.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.50) by $0.02. The business had revenue of $0.01 million during the quarter. As a group, sell-side analysts expect that Fractyl Health, Inc. will post -1.66 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley decreased their target price on shares of Fractyl Health from $18.00 to $10.00 and set an "overweight" rating for the company in a research note on Monday.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in GUTS. Geode Capital Management LLC increased its stake in Fractyl Health by 166.5% during the third quarter. Geode Capital Management LLC now owns 501,476 shares of the company's stock valued at $1,269,000 after purchasing an additional 313,335 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of Fractyl Health by 54.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company's stock valued at $53,000 after buying an additional 7,397 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Fractyl Health by 56.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company's stock worth $204,000 after acquiring an additional 29,262 shares during the last quarter. Barclays PLC lifted its holdings in Fractyl Health by 1,754.7% in the third quarter. Barclays PLC now owns 47,796 shares of the company's stock worth $121,000 after acquiring an additional 45,219 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Fractyl Health during the third quarter valued at approximately $33,000.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.